<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01848262</url>
  </required_header>
  <id_info>
    <org_study_id>B2013:054</org_study_id>
    <nct_id>NCT01848262</nct_id>
  </id_info>
  <brief_title>ECALMIST Versus InSurE in Preterm Infant &lt; 32 Weeks,Multicenter, Multinational RCT</brief_title>
  <acronym>ECALMIST</acronym>
  <official_title>ECALMIST (Early CPAP And Large Volume Minimal Invasive Surfactant Therapy) Versus InSurE (Intubate, Surfactant, Extubate) in Preterm Infants With Respiratory Distress Syndrome (RDS): Prospective Randomised Control Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Manitoba</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Manitoba</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Minimally invasive surfactant therapy via a small vascular catheter - ECALMIST (Early CPAP
      And Large Volume Minimal Invasive Surfactant Therapy) versus InSurE (Intubate, Surfactant
      Extubate) in preterm infants with Respiratory Distress Syndrome (RDS): A prospective
      randomized clinical trial.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After meeting all the inclusion criteria, eligible infants will be randomized to receive
      surfactant either through the ECALMIST or the InSurE methods. The attending neonatologist or
      neonatal team will have full discretion to decide when to intubate and when to extubate or
      wean the infant off the ventilator or NCPAP.

      General guidelines for reintubation include persistent pH&lt;7.20, PaCO2 &gt; 65 mmHg, very
      frequent apnea (&gt;2-3/hour of apneic or bradycardic spells not responsive to corrective
      therapy), frequent desaturations &gt;3/hour not responding to increase in FiO2 or increase in
      FiO2 to 100%), or apneas requiring prolonged PPV. For the purpose of the study a successful
      outcome for the primary objective will have occurred if the infant has not been reintubated
      and ventilated during the initial 3 days of life.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of early ventilation hours</measure>
    <time_frame>3 days</time_frame>
    <description>The number of the newborn infants needed ventilation in the 1st 3 days of life</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Apnea</measure>
    <time_frame>15 minutes</time_frame>
    <description>Pause or stop of breathing for more than 20 seconds or stop of breathing that associated with decrease oxygen saturation below 75% or decrease heart rate below 100 during ECALMIST or InSurE method of surfactant therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bradycardia</measure>
    <time_frame>15 minutes</time_frame>
    <description>Decreased heart rate below 100 beat per minutes during ECALMIST or InSurE procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Desaturation</measure>
    <time_frame>15 minutes</time_frame>
    <description>Decreased level of oxygen saturation measured by pulse oximeter to below 75% for more than 20 seconds during either ECALMIST or InSurE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total ventilation hours</measure>
    <time_frame>hospital admition days</time_frame>
    <description>Number of total hours during which the newborn are ventilated during hospital admission (form delivery till discharge home)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Chronic lung disease</measure>
    <time_frame>1st 2 months of life</time_frame>
    <description>The incidence of Chronic lung disease (CLD) both definitions; the need for oxygen support at 28 days of postnatal life and at the 36 weeks of corrected postnatal age</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Early ventilation hours</measure>
    <time_frame>3 days</time_frame>
    <description>The mean of ventilation hours</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Hospital stay</measure>
    <time_frame>1st three months of life</time_frame>
    <description>The number of days that newborn spent in the hospital after delivery</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Respiratory Distress Syndrome</condition>
  <arm_group>
    <arm_group_label>ECALMIST</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ECALMIST will be used in preterm infants between 24 weeks to 31 weeks in the 1st day of life with RDS and spontaneously breathing with decision to give surfactant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>InSurE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>InSurE will be used in preterm infants between 24 weeks to 31 weeks in the 1st day of life with RDS and spontaneously breathing with decision to give surfactant</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>ECALMIST</intervention_name>
    <description>Surfactant administration via 17 (5 French) gauge, 133 mm length vascular catheter. 5 ml/kg will be drawn up in a 5 or 10 ml syringe. The vascular catheter will be inserted through the vocal cords under direct vision using a standard laryngoscope with the appropriate blade for gestational age. The procedure will be done without removing the NCPAP. A bolus of surfactant of 0.25-0.5 ml will be administered, after observing the surfactant moving up and down as indication of accurate intubation of the trachea. The surfactant will be slowly injected by small pulses of 0.25-0.5 ml over 20-30 seconds, each bolus with 10 seconds apart. At the end of the procedure, the operator will flush the catheter with 0.5 ml of air before removing the catheter.</description>
    <arm_group_label>ECALMIST</arm_group_label>
    <other_name>CPAP and Minimal Invasive Surfactant Therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>InSure</intervention_name>
    <description>Patients who will receive surfactant via this technique will have their NCPAP removed and then they will be orally intubated with a standard endotracheal tube (ETT) using standard endotracheal intubation procedures using appropriate size ETT according to the birth weight. Bovine surfactant will be administered through the ETT using the same technique described above for arm 1. Manual lung inflation using a Jackson -Rees anesthesia bag at 20/5-cm H2O pressure will be performed during the surfactant instillation after which the patient will be extubated promptly as per the discretion of the neonatal team. Immediately following extubation, nCPAP support will be recommenced. No premedication, such as sedation or atropine, will be used during either procedure.</description>
    <arm_group_label>InSurE</arm_group_label>
    <other_name>Intubate surfcatant extubate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        All should apply:

          -  Newborn less than 32 weeks gestation at birth

          -  Postnatal age &lt; 24 hrs of life

          -  Clinical diagnosis of RDS

          -  Spontaneously breathing on NCPAP

          -  Clinical decision to give surfactant.

        Exclusion Criteria:

          -  Lack of parental consent.

          -  Need for mechanical ventilation

          -  Major congenital malformation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>24 Weeks</minimum_age>
    <maximum_age>31 Weeks</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yahya Ethawi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Manitoba</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yahya Ethawi, MD</last_name>
    <phone>2049634721</phone>
    <email>yalethawi@hsc.mb.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Abrar Hussain, MD</last_name>
    <phone>2047719301</phone>
    <email>ahussain3@hsc.mb.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Health sciences Center</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yahya Ethawi, MD</last_name>
      <phone>12049634721</phone>
      <email>yalethawi@hsc.mb.ca</email>
    </contact>
    <contact_backup>
      <last_name>Mohamed Tagin, MD</last_name>
      <phone>12044304250</phone>
      <email>mtagin@hsc.mb.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Yahya Ethawi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ruben Alvaro, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mary Seshia, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Abrar Abrar Hussain, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yasser Ali, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>John Minski, RTT</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mohammad Al Yahmadi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Iram Musharaf, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mohamed Tagin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St Boniface Hospital</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yahya Ethawi, MD</last_name>
      <phone>10249634721</phone>
      <email>yalethawi@hsc.mb.ca</email>
    </contact>
    <contact_backup>
      <last_name>Mohamed Tagin, MD</last_name>
      <phone>12044304250</phone>
      <email>mtagin@hsc.m.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Yahya Ethawi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ruben Alvaro, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mary Seshia, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Abrar Hussain, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>John Misnki, RTT</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yasser Ali, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mohammed Al Yahmadi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Iram Musharaf, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joe Millar, RTT</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mohamed Tagin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 2, 2013</study_first_submitted>
  <study_first_submitted_qc>May 6, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 7, 2013</study_first_posted>
  <last_update_submitted>February 9, 2014</last_update_submitted>
  <last_update_submitted_qc>February 9, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 11, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Manitoba</investigator_affiliation>
    <investigator_full_name>Yahya Al Ethawi</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <keyword>ECALMIST</keyword>
  <keyword>InSurE</keyword>
  <keyword>CPAP</keyword>
  <keyword>Ventilation</keyword>
  <keyword>Vascular Catheter</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Surfactants</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

